Align Technology (ALGN)
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$185.22-1.68%
Close 2026-07-07 · 1-day change
Reading ALGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ALGN free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading ALGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ALGN free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder, focusing on steady revenue growth and margin improvement. The current thesis is stable, supported by recent financial performance and management's commitment to growth targets.
The market appears to have priced in a neutral valuation relative to peers, suggesting that expectations are modest. There is a slight gap in expectations, indicating that the stock may not be overly optimistic compared to its competitors.
Management is on track to achieve revenue growth of 3% to 4% in 2026, with a focus on improving operating margins. However, there is some risk as recent industry trends show peers have been missing earnings, which could impact ALGN's performance.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. Positive earnings and guidance from these companies could support ALGN, while any negative shifts could create headwinds.
In the next 1 to 3 years, ALGN's performance will depend on its ability to execute on growth and margin targets amid industry dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The launch of an AI-powered digital dentistry platform enhances product offerings and growth. Global growth offsets pressure from North American demand.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This growth range will show if Align is on track to meet its full-year revenue target.
Confirms:Q2 2026 revenues reported between $1,040M and $1,060M, indicating growth of 3% to 5%.
Disproves:Q2 2026 revenues fall below $1,040M, indicating growth below 3%.
Why it matters: Growth in Clear Aligner sales is important for Align's income and market share.
Confirms:In Q2 2026, Clear Aligner sales go up from the previous quarter and last year.
Disproves:In Q2 2026, Clear Aligner sales go down from the previous quarter or last year.
Why it matters: This growth range confirms Align's ability to meet its annual target of 3% to 4%.
Confirms:Q2 2026 revenue growth lands between 3% and 5% year-over-year.
Disproves:Q2 2026 revenue growth falls below 3% year-over-year.
Why it matters: Completing this repurchase shows strong cash flow and confidence in Align's strategy.
Confirms:Align finishes the $200 million stock buyback by the October deadline.
Disproves:Align fails to complete the repurchase by October 2026.
Why it matters: This margin shows good cost control and helps with long-term profit.
Confirms:Q2 2026 GAAP operating margin meets or exceeds 16.4%.
Disproves:Q2 2026 GAAP operating margin falls below 16.4%.
Why it matters: Align met its operating margin goal. This shows it can control costs well.
Confirms:The 2026 GAAP operating margin was just under 18%.
Disproves:The 2026 GAAP operating margin was much lower than 18%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.